Tocqueville Asset Management’s Cognition Therapeutics CGTX Stock Holding History

Tocqueville Asset Management’s Portfolio CGTX Stock Details CGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$369K	Buy	320,500 +125,500	+64%	+$149K	﹤0.01%	470
2026 Q1	$148K	Buy	195,000 +2,500	+1%	+$2.91K	﹤0.01%	535
2025 Q4	$260K	Buy	192,500 +30,000	+18%	+$48.7K	﹤0.01%	530
2025 Q3	$219K	Buy	162,500 +134,000	+470%	+$183K	﹤0.01%	530
2025 Q2	$8.83K	Hold	28,500	–	–	﹤0.01%	535
2025 Q1	$12K	Hold	28,500	–	–	﹤0.01%	513
2024 Q4	$20K	Buy	28,500 +5,000	+21%	+$2.47K	﹤0.01%	536
2024 Q3	$11K	Sell	23,500 -16,500	-41%	-$17K	﹤0.01%	527
2024 Q2	$66.4K	Buy	40,000 +14,000	+54%	+$27.9K	﹤0.01%	519
2024 Q1	$47.3K	Buy	+26,000	New	+$53.7K	﹤0.01%	531

Other funds holding CGTX

BCM

BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.17B AUM 42.44% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

HCM

Hilton Capital Management Garden City, New York $1.47B AUM 18.73% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return

Tocqueville Asset Management's CGTX Position: Q2 2026 in Review

Tocqueville Asset Management increased its Cognition Therapeutics (CGTX) stake by 64% in Q2 2026, buying an estimated $149K and bringing the position to 320,500 shares worth $369K. The position accounts for ﹤0.01% of the portfolio, ranked #470.

Tocqueville Asset Management first reported a position in CGTX in Q1 2024 and has held it in 10 quarters since. 66 funds tracked by Wall St. Rank hold CGTX as of Q2 2026.

Tocqueville Asset Management held 320,500 shares of Cognition Therapeutics worth $369K as of Q2 2026.
Tocqueville Asset Management bought 125,500 Cognition Therapeutics shares in Q2 2026, an estimated $149K.
Cognition Therapeutics made up ﹤0.01% of Tocqueville Asset Management's portfolio in Q2 2026, its #470 holding.
Tocqueville Asset Management first reported a position in Cognition Therapeutics in Q1 2024 and has held it in 10 quarters since.
66 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q2 2026.

Based on Tocqueville Asset Management's 13F filing for Q2 2026, filed 10 Aug 2026.